Archives
-
NADH as a Redox Variable in Osteoclast Research
2026-09-10
NADH is more than an energy metabolite: it can be treated as an experimental redox variable when studying osteoclast differentiation, apoptosis, and Sirt6-associated signaling. This article connects reduced nicotinamide adenine dinucleotide handling with the mechanistic findings of a catalpol osteoporosis study while defining practical assay controls and translational limits.
-
Lysosomal Exocytosis in MPS IVA Cartilage
2026-09-09
A 2026 study in zebrafish identifies enhanced lysosomal exocytosis as a feature of GALNS deficiency and connects it to altered cathepsin activity, glycosaminoglycan distribution, and TGFβ/BMP signaling in developing cartilage. The findings extend lysosomal storage disorder biology beyond substrate accumulation and provide a framework for testing how membrane trafficking contributes to skeletal pathology.
-
Chicken Gasdermins Reveal Bird Pyroptosis Mechanisms
2026-09-09
The reference study maps how chicken gasdermins are cleaved by caspases and shows that the resulting amino-terminal fragments can drive membrane damage, cell death, and antibacterial activity. Its findings expand pyroptosis research beyond mammalian models and provide a framework for distinguishing caspase-1- and caspase-3/7-linked pathways in avian infection biology.
-
Syringin, EGFR/PI3K/Akt, and Sunitinib in RCC
2026-09-08
A 2024 Journal of Functional Foods study identifies Syringin as a potential sensitizer to sunitinib in renal cell carcinoma models. By combining network pharmacology, molecular docking, cell-based assays, and pathway-focused immunoblotting, the authors link the observed effects to EGFR/PI3K/Akt signaling and provide a preclinical framework for combination-oriented natural product research.
-
BMX-IN-1 Workflow for BMX Kinase Research
2026-09-08
BMX-IN-1 is an irreversible BMX kinase inhibitor for connecting target engagement with cell-cycle, apoptosis, lysosomal-acidification, and host-pathogen readouts. This workflow translates recent BMX biology into practical assay design while separating validated findings from recommended optimization steps.
-
ABT-199 (GDC-0199), Bcl-2 inhibitor
2026-09-07
ABT-199, also known as Venetoclax or GDC-0199, provides a selective tool for studying BCL-2-dependent survival and the mitochondrial apoptosis pathway in hematologic cancer models. It is suitable for controlled in vitro apoptosis and selectivity experiments, but should not be treated as a broad Mcl-1 inhibitor, a clinical dosing reference, or a diagnostic product.
-
Heparin sodium for Nanovesicle Uptake Studies
2026-09-07
Heparin sodium extends beyond routine coagulation controls as a practical competition probe for heparan sulfate proteoglycan-mediated nanovesicle uptake. This workflow connects anti-factor Xa and aPTT assay discipline with the Cistanche-derived nanovesicle study while clearly separating established evidence from exploratory optimization.
-
EZ Cap™ Firefly Luciferase mRNA Workflow Guide
2026-09-05
Build reproducible mRNA delivery, translation, viability, and imaging workflows around a Cap1 firefly luciferase reporter. Practical guidance connects transcript handling with lipid nanoparticle size control so researchers can distinguish cargo performance from formulation effects.
-
Bafilomycin A1: V-ATPase Workflow Guide
2026-09-04
Bafilomycin A1 enables reversible, nanomolar interrogation of organellar acidification, lysosomal turnover, and osteoclast function. This workflow guide also explains why the compound produced a negative entry result in a grass carp reovirus study—and how to use that finding to design better controls.
-
Resazurin Cell Viability Assay Kit in Redox Biology
2026-09-04
The Resazurin Cell Viability Assay Kit can do more than rank cytotoxic compounds: it can expose how redox-active treatments alter cellular metabolic capacity. This guide connects K2234 assay design with the parthenolide study in lymphoid malignancies to improve interpretation, controls, and mechanistic follow-up.
-
AMPK–p62 Feedback Under Metabolic Stress
2026-09-03
The 2024 Autophagy study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates NRF2 activation with metabolic adaptation during nutrient stress. Its mechanistic model connects lysosomal deacidification, TFEB/TFE3 regulation, ROS-dependent TAK1 signaling, and site-specific p62 phosphorylation, offering a framework for understanding STK11–KEAP1 cooperation in lung cancer.
-
Astrocytic GAT-3 Controls Dentate Gyrus Memory
2026-09-03
The reference study identifies astrocytic GAT-3 as an active signaling element in the entorhinal cortex–dentate gyrus circuit, linking GABA uptake to astrocytic Ca2+ elevation, presynaptic GluN2B-containing NMDAR activity, and contextual fear memory. Its integrated electrophysiological, optogenetic, histological, and behavioral design provides a framework for separating transporter-dependent glial signaling from conventional postsynaptic GABAergic inhibition.
-
DMG-PEG2000-NH2: From SAR to LNP Strategy
2026-09-02
Translational success depends on connecting molecular optimization with a delivery system that can be measured, controlled, and reproduced. This thought-leadership article examines how DMG-PEG2000-NH2 can support amide-linked lipid platforms while using sulfonamide optimization against Mycobacterium tuberculosis as a disciplined example of evidence-led design.
-
CD38 CAR Binders: Structure-Guided Affinity Tuning
2026-09-02
Cheng et al. define how the CD38 CAR binders RP02 and 028 recognize distinct antigen surfaces and differentially influence CD38 enzymatic activity. Structural analysis, alanine scanning, and CAR-T functional testing show that rational affinity attenuation can reduce fratricide while preserving tumor-cell killing.
-
Sulfaphenazole-Derived Sulfonamides for Tuberculosis
2026-09-01
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP2C9 inhibition, a liability associated with drug–drug interactions. Compound 10d combined an MIC of 5.69 μg/mL against M. tuberculosis H37Rv with CYP2C9 inhibition of IC50 >10 μM, providing a useful lead profile for further tuberculosis drug discovery.